In plasma from PD patients with GBA mutations and/or LRRK2-G2019S mutations, increased levels of ganglioside-NANA-3 (a precursor of complex sphingolipids) were observed, possibly due to a reduction in the activity of β-GCase [217]. This evidence concerns the gene GBA1 and Parkinson disease.